The earnings call highlighted significant progress with the BLA submission for INO-3107, successful FDA inspections, and advancements in DNA medicine technology, suggesting a promising outlook. However, concerns over decreased cash reserves and potential competition were noted.

Company Guidance -

Q3 2025

In the Inovio Second Quarter 2025 Financial Results Conference Call, the company provided guidance on several key metrics related to their lead asset, INO-3107. They are on track to submit their Biologics License Application (BLA) for INO-3107 in the second half of 2025, with completion and file acceptance anticipated by year-end. The goal is to obtain priority review, which could lead to a Prescription Drug User Fee Act (PDUFA) date around mid-2026. Financially, Inovio reported a significant reduction in operating expenses, with a 31% decrease from $33.3 million in Q2 2024 to $23.1 million in Q2 2025. Their net loss for Q2 2025 decreased by 27% to $23.5 million, and they ended the quarter with $47.5 million in cash, excluding proceeds from a recent public offering. The company anticipates their cash runway to extend into Q2 2026, bolstered by a $22.5 million raise. They also highlighted progress in commercial preparations, including building distribution strategies and engaging with potential partners.

BLA Submission for INO-3107 on Track

Inovio is on track to submit the Biologics License Application (BLA) for INO-3107 in the second half of 2025. The company plans to request a priority review, potentially leading to a PDUFA date in mid-2026.

Publication of Clinical Data

Data from Inovio's retrospective study on the long-term clinical effect of INO-3107 were published in The Laryngoscope, demonstrating significant clinical benefits for RRP patients, including a reduction in surgeries.

Operating Expenses Reduction

Inovio significantly reduced its operating expenses by 31% in Q2 2025 compared to Q2 2024, reflecting strategic fiscal management.

Successful FDA Inspection

The FDA inspection of Inovio as the clinical sponsor of the Phase I/II trial was successfully completed, marking an important step in the regulatory process.

Expansion of Next-Generation DNA Medicine Technology

Inovio highlighted the potential of their next-generation DNA medicine technology, including DNA-encoded monoclonal antibodies and protein replacement therapies, with ongoing partnerships and data sharing.

Inovio Pharmaceuticals (INO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.42 / -	-0.89	―	―	―
Aug 12, 2025	2025 (Q2)	-0.61 / -0.61	-1.19	48.74% (+0.58)	―
May 13, 2025	2025 (Q1)	-0.69 / -0.51	-1.31	61.07% (+0.80)	―
Mar 18, 2025	2024 (Q4)	-0.84 / -0.65	-1.1	40.91% (+0.45)	―
Nov 14, 2024	2024 (Q3)	-1.15 / -0.89	-1.56	42.95% (+0.67)	―
Aug 08, 2024	2024 (Q2)	-1.10 / -1.19	-1.56	23.72% (+0.37)	―
May 13, 2024	2024 (Q1)	-1.01 / -1.31	-1.92	31.77% (+0.61)	―
Mar 06, 2024	2023 (Q4)	-1.19 / -1.10	-2.64	58.33% (+1.54)	―
Nov 09, 2023	2023 (Q3)	-1.52 / -1.56	-1.8	13.33% (+0.24)	―
Aug 09, 2023	2023 (Q2)	-1.74 / -1.56	-5.52	71.74% (+3.96)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

INO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$1.49	$1.70	+14.09%
May 13, 2025	$1.92	$1.88	-2.08%
Mar 18, 2025	$2.10	$1.96	-6.67%
Nov 14, 2024	$4.77	$4.26	-10.69%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.